The recent development of novel, long-acting antibiotics has prompted exploration in the infectious disease literature of their use for cellulitis in the ED to decrease hospitalizations” Koziatek et al (2017).
Abstract:
Cellulitis is frequently encountered in the emergency department (ED) and is estimated to result in over 700,000 hospital admissions per year [1-3]. The recent development of novel, long-acting antibiotics has prompted exploration in the infectious disease literature of their use for cellulitis in the ED to decrease hospitalizations [4-6]. Dalbavancin is a semisynthetic lipoglycopeptide antibiotic with activity against gram-positive pathogens largely responsible for cellulitis, including methicillin-resistant Staphylococcus aureus (MRSA) [7].
[ctt link=”zIjED” template=”1″]ReTweet if useful… Experience with dalbavancin for cellulitis treatment in the emergency department https://ctt.ec/zIjED+ @ivteam #ivteam[/ctt]
Reference:
Koziatek, C., Mohan, S., Caspers, C., Swaminathan, A. and Swartz, J. (2017) Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit. The American Journal of Emergency Medicine. November 15th. [epub ahead of print].
DOI: http://dx.doi.org/10.1016/j.ajem.2017.11.037
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]